Kane Biotech Inc.

Good day and thank you for standing by. Welcome to the Kean Biotech second quarter 2021 financial results call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. If anyone should require assistance during the conference, please press star then zero on your touchtone telephone. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr. Lorne Gorber. Cain Investor Relations and Global Spokesperson. Please go ahead.

Thank you, May. Good afternoon and welcome to Cain Biotech's Q2 2021 results call. We're delighted to have you join us. With me to review the financial and operating results for the second quarter ended June 30th, 2021, are Cain's CEO, Mark Edwards, and CFO, Ray Dupree. Following prepared remarks, we will open the lines and take your questions. Before handing over to Mark, let me caution you that our comments and discussion will include forward-looking information within the meaning of applicable securities legislation. Forward-looking information will include, among other things, forecasts and projections which involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from such forecasts and projections. Therefore, Although we believe that anticipated future results, performance, or achievements expressed or implied by the forward-looking information are based on reasonable assumptions and expectations, you should not place undue reliance on such forward-looking information. Now, I'll hand the call over to Mark Edwards, Chief Executive of Kane Biotech. Mark.

Thank you, Lorne, and good afternoon, everyone. I'm excited about the momentum we're generating for the second half of this year and into 2022. This is the case across all three of our strategic pillars, animal health, OTC, which has mainly been focused on dermatology, as well as our wound care and surgical business. Both our dispersion B and coactive plus technologies continue to be recognized for their effectiveness in treating biofilms. As a result, the pipeline of licensing and commercial opportunities continues to grow, and discussions with several potential partners are advancing well. There is more and more awareness about biofilms and the related issues and how well Keynes Technologies address these issues. I'll turn it over to Ray now for a summary of the Q2 2021 financials, and then I'll provide a short operational summary and market outlook before taking questions.